Butyrate for Health & Longevity - Quick Reference Sheet

Butyrate for Health & Longevity

Created on 09/26/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Grok 4.5 – Audit

Butyrate is a fatty acid that colon bacteria make from fiber, sold as an oral dietary supplement for gut and metabolic health. Trials report narrow changes in bowel symptoms, weight without diabetes, blood fats, or a liver-fat score not from butyrate alone. Ulcerative colitis results conflict. Blood pressure moved in opposite directions, including a rise after blood-pressure drugs were stopped. Evidence that capsules extend life or prevent cancer is absent. (Full Review)

Protocol

Adult oral sodium butyrate
600 mg, 1.5 g, or 1,875 mg daily
300 mg twice daily for 8 weeks in colitis; 1.5 g or 1,875 mg for 12 weeks, the latter with a reduced-calorie diet
Time of day
With food, split across the day
One liver-fat protocol uses morning, midday, and evening; a single uncoated dose is a poor match to the short plasma presence
Tributyrin
50–400 mg/kg/day
Cancer-trial doses are not supplement practice; plasma butyrate was gone by about 5 hours
Time to effect
Irritable Bowel Symptoms
4–12 weeks
Pain during defecation by 4 weeks; urgency and bowel habit by 12 weeks; pediatric pain response at 8 weeks
Weight Loss Without Diabetes
12 weeks
Extra loss versus placebo read at 12 weeks in adults without diabetes
Triglycerides and Tight Glucose Range in Type 2 Diabetes
12 weeks
Triglycerides and time in a tight glucose range, independent of weight change

Benefits

Contraindications
  • Congestive heart failure, or a prescribed salt-restricted diet
  • Serum sodium above 145 mEq/L
  • Pregnancy or breastfeeding
  • Known intolerance or allergy to butyrate (prior vomiting or rash on a butyrate product)
Key Interactions
  • Blood-pressure drugs (lisinopril, amlodipine; after those drugs were stopped)
  • Histone deacetylase inhibitors (vorinostat)
  • Sodium-containing products (sodium butyrate, sodium antacids)
  • Inulin and fermentable fiber (additive)
  • Antibiotics (amoxicillin, ciprofloxacin)

Risk & Side Effects

  • High:
  • Medium: Nausea and related symptoms at high tributyrin doses
  • Low: Blood pressure change; direction depends on route and on whether blood-pressure drugs were stopped
  • Speculative: Off-target gene effects at high plasma levels; no human harm shown at supplement doses

Monitoring

Marker Target Why
Blood pressure Below 120/80 mm Hg Trials moved pressure in both directions
Fasting triglycerides Below 100 mg/dL Fell in one diabetes trial
Glycated hemoglobin Below 5.4 percent Longer glucose exposure
Fasting glucose 75–90 mg/dL Pairs with glycated hemoglobin
High-sensitivity C-reactive protein Below 1.0 mg/L Background inflammation
Body weight Change from personal baseline Non-diabetes trial outcome
Symptom score Change from the person's own baseline People with bowel symptoms
Fecal calprotectin Change from the person's own baseline If inflammatory bowel disease is already diagnosed, through usual care

Cadence: Baseline before the first dose for seated morning blood pressure, body weight, and fasting triglycerides, glucose, and glycated hemoglobin. Blood pressure again at about 4 weeks. Weight, triglycerides, glucose, and glycated hemoglobin at 12 weeks, then every 6–12 months if use continues.

Qualitative Assessment

  • Bowel comfort: pain with defecation, urgency, bloating, and stool form across 4–12 weeks
  • Odor, cramping, nausea, or a new headache after a dose change
  • Daytime energy and, in postmenopausal women, ease of grip and a short walk
  • Sleep quality, recorded because a colitis trial measured it, without a settled direction